Leflunomide in combination therapy for rheumatoid arthritis.
Savage
Ruth L
RL
New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. ruth.savage@otago.ac.nz
D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001315:Australia / Q000453:epidemiology; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D006801:Humans; D007239:Infections / Q000453:epidemiology; D007555:Isoxazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D000077339:Leflunomide; D008727:Methotrexate / Q000009:adverse effects; D009520:New Zealand / Q000453:epidemiology; D010198:Pancytopenia / Q000139:chemically induced; D011014:Pneumonia / Q000139:chemically induced
D018501:Antirheumatic Agents; D007555:Isoxazoles; D000077339:Leflunomide; D008727:Methotrexate